Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Growth Hormone Excess: Implications and Management

Author(s): Suneela Dhaneshwar*, Shrishti Shandily and Vatsalya Tiwari

Volume 23, Issue 6, 2023

Published on: 29 December, 2022

Page: [748 - 763] Pages: 16

DOI: 10.2174/1871530322666221012155533

Price: $65

Abstract

Acromegaly is described as the oversecretion of growth hormone (GH) and, subsequently, insulin-like growth factor 1 (IGF-1), ascribed in most cases to a pituitary adenoma. This disease presents a progressive disfigurement, along with other systemic manifestations, which altogether diminishes the quality of life in the patients. Prolonged exposure to abnormally high levels of GH and IGF-1 levels results in cardiovascular, cerebrovascular, and pulmonary dysfunction which overall produces a fall in life expectancy. Timely diagnosis and further treatment decreased the mortality rate of the patients and showed an improvement in the quality of life. Surgical procedures, advanced radiation therapy tools, and the availability of pharmacological compounds that act on pituitary growth hormone-producing cells have enabled an improved approach to treating the disease. Pharmacological treatment is currently an important management option, and it may also be the first-line treatment in patients with acromegaly who do not benefit from or are ineligible for first-line surgical procedures. From its inception until 2021, we used a comprehensive search strategy on Medline/PubMed, Scopus, Embase, Web of Science, and the Cochrane Library electronic databases. All human research articles and review articles published in English were considered for the review. In this review, we describe the clinical implications and management of patients with acromegaly, consisting of scientific improvements underlying the developing understanding of pathogenesis and diagnosis, associated comorbidities and mortality rate with the disease, and major improvements in the treatment of the disease, along with novel strategies including quality of life and patient-reported outcomes.

« Previous Next »
Graphical Abstract

[1]
Katznelson, L. Diagnosis and treatment of acromegaly. Growth Horm. IGF Res., 2005, 15, 31-35.
[http://dx.doi.org/10.1016/j.ghir.2005.06.007] [PMID: 16023876]
[2]
O’Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66(3), 1500-1508.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2925] [PMID: 16452206]
[3]
Medical progress: Acromegaly. N. Engl. J. Med., 2007, 356(8), 879-879.
[http://dx.doi.org/10.1056/NEJMx070007]
[4]
Lopes, M.B.S. Growth hormone-secreting adenomas: Pathology and cell biology. Neurosurg. Focus, 2010, 29(4), E2.
[http://dx.doi.org/10.3171/2010.7.FOCUS10169] [PMID: 20887127]
[5]
Horvath, E.; Kovacs, K. Pathology of acromegaly. Neuroendocrinology, 2006, 83(3-4), 161-165.
[http://dx.doi.org/10.1159/000095524] [PMID: 17047379]
[6]
Mete, O.; Lopes, M.B. Overview of the 2017 WHO Classification of pituitary tumors. Endocr. Pathol., 2017, 28(3), 228-243.
[http://dx.doi.org/10.1007/s12022-017-9498-z] [PMID: 28766057]
[7]
Kovacs, K. Tumors of the pituitary gland. In: Atlases of Tumor and Non-tumor Pathology; American Registry of Pathology: United States, 1986; pp. 1-269.
[8]
Kiseljak, V.K.; Carlson, N.E.; Borges, M.T.; DeMasters, K.B.K.; Lillehei, K.O.; Kerr, J.M.; Wierman, M.E. Growth hormone tumor histo-logical subtypes predict response to surgical and medical therapy. Endocrine, 2015, 49(1), 231-241.
[http://dx.doi.org/10.1007/s12020-014-0383-y] [PMID: 25129651]
[9]
Brzana, J.; Yedinak, C.G.; Gultekin, S.H.; Delashaw, J.B.; Fleseriu, M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary, 2013, 16(4), 490-498.
[http://dx.doi.org/10.1007/s11102-012-0445-1] [PMID: 23184260]
[10]
Larkin, S.; Reddy, R.; Karavitaki, N.; Cudlip, S.; Wass, J.; Ansorge, O. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naïve patients with somatotroph adenomas. Eur. J. Endocrinol., 2013, 168(4), 491-499.
[http://dx.doi.org/10.1530/EJE-12-0864] [PMID: 23288882]
[11]
Obari, A.; Sano, T.; Ohyama, K.; Kudo, E.; Qian, Z.R.; Yoneda, A.; Rayhan, N.; Mustafizur, R.M.; Yamada, S. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol., 2008, 19(2), 82-91.
[http://dx.doi.org/10.1007/s12022-008-9029-z] [PMID: 18629656]
[12]
Bakhtiar, Y.; Hirano, H.; Arita, K.; Yunoue, S.; Fujio, S.; Tominaga, A.; Sakoguchi, T.; Sugiyama, K.; Kurisu, K.; Yasufuku, T.J.; Takano, K. Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol., 2010, 163(4), 531-539.
[http://dx.doi.org/10.1530/EJE-10-0586] [PMID: 20688896]
[13]
Akirov, A.; Asa, S.L.; Amer, L.; Shimon, I.; Ezzat, S. The clinicopathological spectrum of acromegaly. J. Clin. Med., 2019, 8(11), 1962.
[http://dx.doi.org/10.3390/jcm8111962] [PMID: 31766255]
[14]
Kreutzer, J.; Vance, M.L.; Lopes, M.B.S.; Laws, E.R., Jr Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J. Clin. Endocrinol. Metab., 2001, 86(9), 4072-4077.
[http://dx.doi.org/10.1210/jcem.86.9.7819] [PMID: 11549628]
[15]
Melmed, S. Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol., 2011, 7(5), 257-266.
[http://dx.doi.org/10.1038/nrendo.2011.40] [PMID: 21423242]
[16]
Horvath, E.; Kovacs, K.; Singer, W.; Smyth, H.S.; Killinger, D.W.; Erzin, C.; Weiss, M.H. Acidophil stem cell adenoma of the human pituitary: Clinicopathologic analysis of 15 cases. Cancer, 1981, 47(4), 761-771.
[http://dx.doi.org/10.1002/1097-0142(19810215)47:4<761::AID-CNCR2820470422>3.0.CO;2-L] [PMID: 6261917]
[17]
Chin, S.O.; Hwang, J.K.; Rhee, S.Y.; Chon, S.; Oh, S.; Lee, M.; Pellegata, N.S.; Kim, S.W. Acromegaly due to a macroinvasive plurihormonal pituitary adenoma and a rectal carcinoid tumor. Endocrinol. Metab., 2015, 30(3), 389-394.
[http://dx.doi.org/10.3803/EnM.2015.30.3.389] [PMID: 25559714]
[18]
Wade, A.N.; Baccon, J.; Grady, M.S.; Judy, K.D.; O’Rourke, D.M.; Snyder, P.J. Clinically silent somatotroph adenomas are common. Eur. J. Endocrinol., 2011, 165(1), 39-44.
[http://dx.doi.org/10.1530/EJE-11-0216] [PMID: 21493729]
[19]
Sansur, C.A.; Oldfield, E.H. Pituitary carcinoma. Semin. Oncol., 2010, 37(6), 591-593.
[20]
Morokuma, H.; Ando, T.; Hayashida, T.; Horie, I.; Inoshita, N.; Murata, F.; Ueki, I.; Nakamura, K.; Imaizumi, M.; Kawakami, A. A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment. Case Rep. Endocrinol., 2012, 2012, 645914.
[http://dx.doi.org/10.1155/2012/645914]
[21]
Scheithauer, B.W.; Kovacs, K.; Nose, V.; Lombardero, M.; Osamura, Y.R.; Lloyd, R.V.; Horvath, E.; Pagenstecher, A.; Bohl, J.E.; Tews, D.S. Multiple endocrine neoplasia type 1–associated thyrotropin-producing pituitary carcinoma: Report of a probable de novo example. Hum. Pathol., 2009, 40(2), 270-278.
[http://dx.doi.org/10.1016/j.humpath.2008.06.013] [PMID: 18755492]
[22]
Sinclair, G.; Olsson, M.; Benmakhlouf, H.; Al-Saffar, Y.; Johnstone, P.; Hatiboglu, M.A.; Shamikh, A. Pituitary carcinomas: Rare and challenging. Surg. Neurol. Int., 2019, 10, 161.
[PMID: 31528496]
[23]
Balili, I.; Sullivan, S.; Mckeever, P.; Barkan, A. Pituitary carcinoma with endolymphatic sac metastasis. Pituitary, 2014, 17(3), 210-213.
[http://dx.doi.org/10.1007/s11102-013-0489-x] [PMID: 23645293]
[24]
Thakker, R.V. Multiple endocrine neoplasia type 1. In: Principles of Molecular Medicine; Springer: Heidelberg, Germany, 2006; pp. 386-392.
[http://dx.doi.org/10.1007/978-1-59259-963-9_39]
[25]
Salenave, S.; Boyce, A.M.; Collins, M.T.; Chanson, P. Acromegaly and McCune-Albright syndrome. J. Clin. Endocrinol. Metab., 2014, 99(6), 1955-1969.
[http://dx.doi.org/10.1210/jc.2013-3826] [PMID: 24517150]
[26]
Bertherat, J. Carney Complex (CNC). Orphanet J. Rare Dis., 2006, 1(1), 21.
[http://dx.doi.org/10.1186/1750-1172-1-21] [PMID: 16756677]
[27]
Thorner, M.O.; Perryman, R.L.; Cronin, M.J.; Rogol, A.D.; Draznin, M.; Johanson, A.; Vale, W.; Horvath, E.; Kovacs, K. Somatotroph hyperplasia. J. Clin. Invest., 1982, 70(5), 965-977.
[http://dx.doi.org/10.1172/JCI110708] [PMID: 6290540]
[28]
Beuschlein, F.; Strasburger, C.J.; Siegerstetter, V.; Moradpour, D.; Lichter, P.; Bidlingmaier, M.; Blum, H.E.; Reincke, M. Acromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphoma. N. Engl. J. Med., 2000, 342(25), 1871-1876.
[http://dx.doi.org/10.1056/NEJM200006223422504] [PMID: 10861322]
[29]
Doga, M.; Bonadonna, S.; Burattin, A.; Giustina, A. Ectopic secretion of Growth Hormone-Releasing Hormone (GHRH) in neuroendocrine tumors: Relevant clinical aspects. Ann. Oncol., 2001, 12(Suppl. 2), S89-S94.
[http://dx.doi.org/10.1093/annonc/12.suppl_2.S89] [PMID: 11762359]
[30]
Cordero, R.A.; Barkan, A.L. Current diagnosis of acromegaly. Rev. Endocr. Metab. Disord., 2008, 9(1), 13-19.
[http://dx.doi.org/10.1007/s11154-007-9060-2] [PMID: 18236162]
[31]
Alexopoulou, O.; Bex, M.; Kamenicky, P.; Mvoula, A.B.; Chanson, P.; Maiter, D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary, 2014, 17(1), 81-89.
[http://dx.doi.org/10.1007/s11102-013-0471-7] [PMID: 23446424]
[32]
Clemmons, D.R. Clinical laboratory indices in the treatment of acromegaly. Clin. Chim. Acta, 2011, 412(5-6), 403-409.
[http://dx.doi.org/10.1016/j.cca.2010.11.008] [PMID: 21075098]
[33]
Clemmons, D.R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem., 2011, 57(4), 555-559.
[http://dx.doi.org/10.1373/clinchem.2010.150631] [PMID: 21285256]
[34]
Rosario, P.W.; Calsolari, M.R. Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary, 2012, 15(2), 179-183.
[http://dx.doi.org/10.1007/s11102-011-0302-7] [PMID: 21380935]
[35]
Schneider, H.J.; Kosilek, R.P.; Günther, M.; Roemmler, J.; Stalla, G.K.; Sievers, C.; Reincke, M.; Schopohl, J.; Würtz, R.P. A novel ap-proach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. J. Clin. Endocrinol. Metab., 2011, 96(7), 2074-2080.
[http://dx.doi.org/10.1210/jc.2011-0237] [PMID: 21508144]
[36]
Freda, P.U.; Post, K.D.; Powell, J.S.; Wardlaw, S.L. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J. Clin. Endocrinol. Metab., 1998, 83(11), 3808-3816.
[http://dx.doi.org/10.1210/jc.83.11.3808] [PMID: 9814451]
[37]
Giustina, A.; Chanson, P.; Bronstein, M.D.; Klibanski, A.; Lamberts, S.; Casanueva, F.F.; Trainer, P.; Ghigo, E.; Ho, K.; Melmed, S. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab., 2010, 95(7), 3141-3148.
[http://dx.doi.org/10.1210/jc.2009-2670] [PMID: 20410227]
[38]
Daud, S.; Hamrahian, A.H.; Weil, R.J.; Hamaty, M.; Prayson, R.A.; Olansky, L. Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration? Pituitary, 2011, 14(4), 414-417.
[http://dx.doi.org/10.1007/s11102-009-0205-z] [PMID: 19904612]
[39]
Lecoq, A.L.; Kamenický, P.; Guiochonl, M.A.; Chanson, P. Genetic mutations in sporadic pituitary adenomas—what to screen for? Nat. Rev. Endocrinol., 2015, 11(1), 43-54.
[http://dx.doi.org/10.1038/nrendo.2014.181] [PMID: 25350067]
[40]
Petrossians, P.; Daly, A.F.; Natchev, E.; Maione, L.; Blijdorp, K.; Sahnoun, F.M.; Auriemma, R.; Diallo, A.M.; Hulting, A.L.; Ferone, D.; Hana, V., Jr; Filipponi, S.; Sievers, C.; Nogueira, C.; Fajardo, M.C.; Carvalho, D.; Hana, V.; Stalla, G.K.; Jaffrain, R.M.L.; Delemer, B.; Colao, A.; Brue, T.; Neggers, S.J.C.M.M.; Zacharieva, S.; Chanson, P.; Beckers, A. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database. Endocr. Relat. Cancer, 2017, 24(10), 505-518.
[http://dx.doi.org/10.1530/ERC-17-0253] [PMID: 28733467]
[41]
Chanson, P.; Salenave, S.; Kamenicky, P. Acromegaly. Handb. Clin. Neurol., 2014, 124, 197-219.
[http://dx.doi.org/10.1016/B978-0-444-59602-4.00014-9] [PMID: 25248589]
[42]
Colao, A.; Ferone, D.; Marzullo, P.; Lombardi, G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr. Rev., 2004, 25(1), 102-152.
[http://dx.doi.org/10.1210/er.2002-0022] [PMID: 14769829]
[43]
Bondanelli, M.; Ambrosio, M.R.; Degli, U.E.C. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary, 2001, 4(4), 239-249.
[http://dx.doi.org/10.1023/A:1020798430884] [PMID: 12501974]
[44]
Vitale, G.; Pivonello, R.; Auriemma, R.S.; Guerra, E.; Milone, F.; Savastano, S.; Lombardi, G.; Colao, A. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin. Endocrinol., 2005, 63(4), 470-476.
[http://dx.doi.org/10.1111/j.1365-2265.2005.02370.x] [PMID: 16181242]
[45]
Hunter, J.J.; Chien, K.R. Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med., 1999, 341(17), 1276-1283.
[http://dx.doi.org/10.1056/NEJM199910213411706] [PMID: 10528039]
[46]
Hejtmancik, M.R.; Bradfield, J.Y., Jr; Herrman, G.R. Acromegaly and the heart: A clinical and pathologic study. Ann. Intern. Med., 1951, 34(6), 1445-1456.
[http://dx.doi.org/10.7326/0003-4819-34-6-1445] [PMID: 14838506]
[47]
Lie, J.T.; Grossman, S.J. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am. Heart J., 1980, 100(1), 41-52.
[http://dx.doi.org/10.1016/0002-8703(80)90277-X] [PMID: 6446234]
[48]
Colao, A.; Marzullo, P.; Di Somma, C.; Lombardi, G. Growth hormone and the heart. Clin. Endocrinol., 2001, 54(2), 137-154.
[http://dx.doi.org/10.1046/j.1365-2265.2001.01218.x] [PMID: 11207626]
[49]
Courville, C. The heart in acromegaly. Arch. Intern. Med., 1938, 61(5), 704-713.
[http://dx.doi.org/10.1001/archinte.1938.00180100014002]
[50]
Colao, A.; Spiezia, S.; Cerbone, G.; Pivonello, R.; Marzullo, P.; Ferone, D.; Di Somma, C.; Assanti, A.P.; Lombardi, G. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin. Endocrinol., 2001, 54(4), 515-524.
[http://dx.doi.org/10.1046/j.1365-2265.2001.01256.x] [PMID: 11318788]
[51]
Paisley, A.N.; Banerjee, M.; Rezai, M.; Schofield, R.E.; Balakrishnannair, S.; Herbert, A.; Lawrance, J.A.L.; Trainer, P.J.; Cruickshank, J.K. Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J. Clin. Endocrinol. Metab., 2011, 96(5), 1486-1492.
[http://dx.doi.org/10.1210/jc.2010-2225] [PMID: 21346071]
[52]
Akutsu, H.; Kreutzer, J.; Wasmeier, G.; Ropers, D.; Rost, C.; Möhlig, M.; Wallaschofski, H.; Buchfelder, M.; Schöfl, C. Acromegaly per se does not increase the risk for coronary artery disease. Eur. J. Endocrinol., 2010, 162(5), 879-886.
[http://dx.doi.org/10.1530/EJE-09-0945] [PMID: 20145047]
[53]
Cannavo, S.; Almoto, B.; Cavalli, G.; Squadrito, S.; Romanello, G.; Vigo, M.T.; Fiumara, F.; Benvenga, S.; Trimarchi, F. Acromegaly and coronary disease: An integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J. Clin. Endocrinol. Metab., 2006, 91(10), 3766-3772.
[http://dx.doi.org/10.1210/jc.2005-2857] [PMID: 16835284]
[54]
Melmed, S. Acromegaly and cancer: not a problem? J. Clin. Endocrinol. Metab., 2001, 86(7), 2929-2934.
[http://dx.doi.org/10.1210/jcem.86.7.7635] [PMID: 11443145]
[55]
Grunstein, R.R.; Ho, K.Y.; Sullivan, C.E. Sleep apnea in acromegaly. Ann. Intern. Med., 1991, 115(7), 527-532.
[http://dx.doi.org/10.7326/0003-4819-115-7-527] [PMID: 1883121]
[56]
Grunstein, R.R.; Ho, K.Y.; Berthon, J.M.; Stewart, D.; Sullivan, C.E. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am. J. Respir. Crit. Care Med., 1994, 150(2), 496-502.
[http://dx.doi.org/10.1164/ajrccm.150.2.8049836] [PMID: 8049836]
[57]
Katznelson, L.; Atkinson, J.L.D.; Cook, D.M.; Ezzat, S.Z.; Hamrahian, A.H.; Miller, K.K.; Ludlam, W.H.; Samson, S.L.; Waguespack, S.G. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr. Pract., 2011, 17(4), 636-646.
[http://dx.doi.org/10.4158/EP.17.4.636] [PMID: 21846616]
[58]
Kropf, L.L.; Madeira, M.; Neto, L.V.; Roberto, G.M.; De Farias, M.L.F. Functional evaluation of the joints in acromegalic patients and associated factors. Clin. Rheumatol., 2013, 32(7), 991-998.
[http://dx.doi.org/10.1007/s10067-013-2219-1] [PMID: 23512376]
[59]
Mazziotti, G.; Bianchi, A.; Porcelli, T.; Mormando, M.; Maffezzoni, F.; Cristiano, A.; Giampietro, A.; De Marinis, L.; Giustina, A. Vertebral fractures in patients with acromegaly: A 3-year prospective study. J. Clin. Endocrinol. Metab., 2013, 98(8), 3402-3410.
[http://dx.doi.org/10.1210/jc.2013-1460] [PMID: 23771918]
[60]
Lieberman, S.A.; Björkengren, A.G.; Hoffman, A.R. Rheumatologic and skeletal changes in acromegaly. Endocrinol. Metab. Clin. North Am., 1992, 21(3), 615-631.
[http://dx.doi.org/10.1016/S0889-8529(18)30205-6] [PMID: 1521515]
[61]
Claessen, K.M.J.A.; Mazziotti, G.; Biermasz, N.R.; Giustina, A. Bone and joint disorders in acromegaly. Neuroendocrinology, 2016, 103(1), 86-95.
[http://dx.doi.org/10.1159/000375450] [PMID: 25633971]
[62]
Podgorski, M.; Robinson, B.; Weissberger, A.; Stiel, J.; Wang, S.; Brooks, P.M. Articular manifestations of acromegaly. Aust. N. Z. J. Med., 1988, 18(1), 28-35.
[http://dx.doi.org/10.1111/j.1445-5994.1988.tb02236.x] [PMID: 3395299]
[63]
Rizza, R.A.; Mandarino, L.J.; Gerich, J.E. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes, 1982, 31(8), 663-669.
[http://dx.doi.org/10.2337/diab.31.8.663] [PMID: 6761205]
[64]
Melmed, S.; Ho, K.; Klibanski, A.; Reichlin, S.; Thorner, M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J. Clin. Endocrinol. Metab., 1995, 80(12), 3395-3402.
[PMID: 8530571]
[65]
Sönksen, P.H.; Greenwood, F.C.; Ellis, J.P.; Lowy, C.; Rutherford, A.; Nabarro, J.D.N. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J. Clin. Endocrinol. Metab., 1967, 27(10), 1418-1430.
[http://dx.doi.org/10.1210/jcem-27-10-1418] [PMID: 6057823]
[66]
Møller, N.; Jørgensen, J.O.L.; Abildgärd, N.; Ørskov, L.; Schmitz, O.; Christiansen, J.S. Effects of growth hormone on glucose metabolism. Horm. Res., 1991, 36(1), 32-35.
[http://dx.doi.org/10.1159/000182185] [PMID: 1806481]
[67]
Hoogenberg, K.; Sluiter, W.I.; Dullaart, R.P.F. Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency. Eur. J. Endocrinol., 1993, 129(2), 151-157.
[http://dx.doi.org/10.1530/acta.0.1290151] [PMID: 8372600]
[68]
Manara, R.; Maffei, P.; Citton, V.; Rizzati, S.; Bommarito, G.; Ermani, M.; Albano, I.; Della Puppa, A.; Carollo, C.; Pavesi, G.; Scanarini, M.; Ceccato, F.; Sicolo, N.; Mantero, F.; Scaroni, C.; Martini, C. Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature. J. Clin. Endocrinol. Metab., 2011, 96(5), 1292-1300.
[http://dx.doi.org/10.1210/jc.2010-2721] [PMID: 21307138]
[69]
Manara, R.; Bommarito, G.; Rizzati, S.; Briani, C.; Puppa, A.D.; Citton, V.; Zanchetta, E.; Zerbo, F.; Ermani, M.; Martini, C.; Mantero, F.; Sicolo, N.; Maffei, P.; Scaroni, C. Herniation of cerebellar tonsils in acromegaly: prevalence, pathogenesis and clinical impact. Pituitary, 2013, 16(1), 122-130.
[http://dx.doi.org/10.1007/s11102-012-0385-9] [PMID: 22485017]
[70]
Mestrón, A.; Webb, S.M.; Astorga, R.; Benito, P.; Catalá, M.; Gaztambide, S.; Gómez, J.M.; Halperín, I.; Lucas, M.T.; Moreno, B.; Obiols, G.; De Pablos, P.; Paramo, C.; Pico, A.; Torres, E.; Varela, C.; Vazquez, J.A.; Zamora, J.; Albareda, M.; Gilabert, M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol., 2004, 151(4), 439-446.
[http://dx.doi.org/10.1530/eje.0.1510439] [PMID: 15476442]
[71]
Kameyama, S.; Tanaka, R.; Hasegawa, A.; Tamura, T.; Kuroki, M. Subclinical carpal tunnel syndrome in acromegaly. Neurol. Med. Chir., 1993, 33(8), 547-551.
[http://dx.doi.org/10.2176/nmc.33.547] [PMID: 7692327]
[72]
Giustina, A.; Gola, M.; Colao, A.; De Marinis, L.; Losa, M.; Sicolo, N.; Ghigo, E. The management of the patient with acromegaly and headache: A still open clinical challenge. J. Endocrinol. Invest., 2008, 31(10), 919-924.
[http://dx.doi.org/10.1007/BF03346442] [PMID: 19092299]
[73]
Pantanetti, P.; Sonino, N.; Arnaldi, G.; Boscaro, M. Self image and quality of life in acromegaly. Pituitary, 2002, 5(1), 17-19.
[http://dx.doi.org/10.1023/A:1022145116901] [PMID: 12638721]
[74]
Szcześniak, D.; Jawiarczyk, P.A.; Rymaszewska, J. The quality of life and psychological, social and cognitive functioning of patients with acromegaly. Adv. Clin. Exp. Med., 2015, 24(1), 167-172.
[http://dx.doi.org/10.17219/acem/38156] [PMID: 25923102]
[75]
Pereira, A.M.; Tiemensma, J.; Romijn, J.A.; Biermasz, N.R. Cognitive impairment and psychopathology in patients with pituitary diseases. Neth. J. Med., 2012, 70(6), 255-260.
[PMID: 22859416]
[76]
Lugo, G.; Pena, L.; Cordido, F. Clinical manifestations and diagnosis of acromegaly. Int. J. Endocrinol., 2012, 2012, 540398.
[http://dx.doi.org/10.1155/2012/540398]
[77]
Rokkas, T.; Pistiolas, D.; Sechopoulos, P.; Margantinis, G.; Koukoulis, G. Risk of colorectal neoplasm in patients with acromegaly: A meta-analysis. World J. Gastroenterol., 2008, 14(22), 3484-3489.
[http://dx.doi.org/10.3748/wjg.14.3484] [PMID: 18567075]
[78]
Wolinski, K.; Czarnywojtek, A.; Ruchala, M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--Meta-analysis and systematic review. PLoS One, 2014, 9(2), e88787.
[http://dx.doi.org/10.1371/journal.pone.0088787] [PMID: 24551163]
[79]
Jenkins, P.J. Cancers associated with acromegaly. Neuroendocrinology, 2006, 83(3-4), 218-223.
[http://dx.doi.org/10.1159/000095531] [PMID: 17047386]
[80]
Bates, A.S.; Van’t Hoff, W.; Jones, J.M.; Clayton, R.N. An audit of outcome of treatment in acromegaly. QJM. Int. J. med., 1993, 86(5), 293-299.
[http://dx.doi.org/10.1093/oxfordjournals.qjmed.a068816] [PMID: 8327647]
[81]
Wright, A.D.; Hill, D.M.; LOWY, C.; Fraser, T. R. Mortality in acromegaly1. QJM. Int. J. Med., 1970, 39(1), 1-16.https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.887.37 47&rep=rep1&type=pdf
[82]
Alexander, L.; Appleton, D.; Hall, R.; Ross, W.M.; Wilkinson, R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol., 1980, 12(1), 71-79.
[http://dx.doi.org/10.1111/j.1365-2265.1980.tb03135.x] [PMID: 7379316]
[83]
Thuesen, L.; Christensen, S.; Weeke, J.; Ørskov, H.; Henningsen, P. A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? Acta Med. Scand., 1988, 223(4), 337-343.
[http://dx.doi.org/10.1111/j.0954-6820.1988.tb15882.x] [PMID: 3369314]
[84]
Orme, S.M.; McNally, R.J.Q.; Cartwright, R.A.; Belchetz, P.E.; Group, U.K.A.S. Mortality and cancer incidence in acromegaly: A retrospective cohort study. J. Clin. Endocrinol. Metab., 1998, 83(8), 2730-2734.
[http://dx.doi.org/10.1210/jc.83.8.2730] [PMID: 9709939]
[85]
Swearingen, B.; Barker, F.G., II; Katznelson, L.; Biller, B.M.K.; Grinspoon, S.; Klibanski, A.; Moayeri, N.; Black, P.M.; Zervas, N.T. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab., 1998, 83(10), 3419-3426.
[http://dx.doi.org/10.1210/jc.83.10.3419] [PMID: 9768641]
[86]
Arosio, M.; Reimondo, G.; Malchiodi, E.; Berchialla, P.; Borraccino, A.; De Marinis, L.; Pivonello, R.; Grottoli, S.; Losa, M.; Cannavò, S.; Minuto, F.; Montini, M.; Bondanelli, M.; De Menis, E.; Martini, C.; Angeletti, G.; Velardo, A.; Peri, A.; Faustini, F.M.; Tita, P.; Pigliaru, F.; Borretta, G.; Scaroni, C.; Bazzoni, N.; Bianchi, A.; Appetecchia, M.; Cavagnini, F.; Lombardi, G.; Ghigo, E.; Beck, P.P.; Colao, A.; Terzolo, M. Predictors of morbidity and mortality in acromegaly: An Italian survey. Eur. J. Endocrinol., 2012, 167(2), 189-198.
[http://dx.doi.org/10.1530/EJE-12-0084] [PMID: 22596288]
[87]
Ayuk, J.; Clayton, R.N.; Holder, G.; Sheppard, M.C.; Stewart, P.M.; Bates, A.S. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab., 2004, 89(4), 1613-1617.
[http://dx.doi.org/10.1210/jc.2003-031584] [PMID: 15070920]
[88]
Dekkers, O.M.; Biermasz, N.R.; Pereira, A.M.; Romijn, J.A.; Vandenbroucke, J.P. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab., 2008, 93(1), 61-67.
[http://dx.doi.org/10.1210/jc.2007-1191] [PMID: 17971431]
[89]
Giustina, A.; Barkan, A.; Casanueva, F.F.; Cavagnini, F.; Frohman, L.; Ho, K.; Veldhuis, J.; Wass, J.; Von Werder, K.; Melmed, S. Criteria for cure of acromegaly: A consensus statement. J. Clin. Endocrinol. Metab., 2000, 85(2), 526-529.
[http://dx.doi.org/10.1210/jc.85.2.526] [PMID: 10690849]
[90]
Abosch, A.; Tyrrell, J.B.; Lamborn, K.R.; Hannegan, L.T.; Applebury, C.B.; Wilson, C.B. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J. Clin. Endocrinol. Metab., 1998, 83(10), 3411-3418.
[http://dx.doi.org/10.1210/jcem.83.10.5111] [PMID: 9768640]
[91]
Stoller, W.A. Changing paradigms in the surgical and medical management of acromegaly. Expert Rev. Anticancer Ther., 2006, 6(1), 47-53.
[http://dx.doi.org/10.1586/14737140.6.9s.S47]
[92]
Giustina, A.; Barkhoudarian, G.; Beckers, A.; Ben, S.A.; Biermasz, N.; Biller, B.; Boguszewski, C.; Bolanowski, M.; Bollerslev, J.; Bonert, V.; Bronstein, M.D.; Buchfelder, M.; Casanueva, F.; Chanson, P.; Clemmons, D.; Fleseriu, M.; Formenti, A.M.; Freda, P.; Gadelha, M.; Geer, E.; Gurnell, M.; Heaney, A.P.; Ho, K.K.Y.; Ioachimescu, A.G.; Lamberts, S.; Laws, E.; Losa, M.; Maffei, P.; Mamelak, A.; Mercado, M.; Molitch, M.; Mortini, P.; Pereira, A.M.; Petersenn, S.; Post, K.; Puig, D.M.; Salvatori, R.; Samson, S.L.; Shimon, I.; Strasburger, C.; Swearingen, B.; Trainer, P.; Vance, M.L.; Wass, J.; Wierman, M.E.; Yuen, K.C.J.; Zatelli, M.C.; Melmed, S. Multidisciplinary management of acromegaly: A consensus. Rev. Endocr. Metab. Disord., 2020, 21(4), 667-678.
[http://dx.doi.org/10.1007/s11154-020-09588-z] [PMID: 32914330]
[93]
Katznelson, L.; Atkinson, J.L.D.; Cook, D.M.; Ezzat, S.Z.; Hamrahian, A.H.; Miller, K.K. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update: Executive summary. Endocr. Pract., 2011, 17(4), 636-646.
[http://dx.doi.org/10.4158/EP.17.4.636] [PMID: 21846619]
[94]
Melmed, S.; Casanueva, F.F.; Cavagnini, F.; Chanson, P.; Frohman, L.; Grossman, A.; Ho, K.; Kleinberg, D.; Lamberts, S.; Laws, E.; Lombardi, G.; Vance, M.L.; Werder, K.V.; Wass, J.; Giustina, A. Guidelines for acromegaly management. J. Clin. Endocrinol. Metab., 2002, 87(9), 4054-4058.
[http://dx.doi.org/10.1210/jc.2002-011841] [PMID: 12213843]
[95]
Hanson, M.; Li, H.; Geer, E.; Karimi, S.; Tabar, V.; Cohen, M.A. Perioperative management of endoscopic transsphenoidal pituitary surgery. World J. Otorhinolaryngol. Head Neck Surg., 2020, 6(2), 84-93.
[http://dx.doi.org/10.1016/j.wjorl.2020.01.005] [PMID: 32596652]
[96]
Gao, Y.; Zhong, C.; Wang, Y.; Xu, S.; Guo, Y.; Dai, C.; Zheng, Y.; Wang, Y.; Luo, Q.; Jiang, J. Endoscopic versus microscopic transsphenoidal pituitary adenoma surgery: a meta-analysis. World J. Surg. Oncol., 2014, 12(1), 94.
[http://dx.doi.org/10.1186/1477-7819-12-94] [PMID: 24721812]
[97]
Chen, C.J.; Ironside, N.; Pomeraniec, I.J.; Chivukula, S.; Buell, T.J.; Ding, D.; Taylor, D.G.; Dallapiazza, R.F.; Lee, C.C.; Bergsneider, M. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir., 2017, 159(11), 2193-2207.
[http://dx.doi.org/10.1007/s00701-017-3318-6] [PMID: 28913667]
[98]
Marquez, Y.; Tuchman, A.; Zada, G. Surgery and radiosurgery for acromegaly: A review of indications, operative techniques, outcomes, and complications. Int. J. Endocrinol., 2012, 2012, 16289354.
[99]
Elbaum, M.; Mizera, Ł.; Bolanowski, M. The real costs of acromegaly: analysis of different therapies. Endokrynol. Pol., 2019, 70(1), 74-85.
[http://dx.doi.org/10.5603/EP.a2018.0080] [PMID: 30843180]
[100]
Melmed, S. Acromegaly pathogenesis and treatment. J. Clin. Invest., 2009, 119(11), 3189-3202.
[http://dx.doi.org/10.1172/JCI39375] [PMID: 19884662]
[101]
Ayuk, J.; Sheppard, M.C. Growth hormone and its disorders. Postgrad. Med. J., 2006, 82(963), 24-30.
[http://dx.doi.org/10.1136/pgmj.2005.036087] [PMID: 16397076]
[102]
Gomes, P.M.; Cárdenas, S.J.; Álvarez, E.C. Somatostatin analogs in clinical practice: A review. Int. J. Mol. Sci., 2020, 21(5), 1682.
[http://dx.doi.org/10.3390/ijms21051682] [PMID: 32121432]
[103]
Gariani, K.; Meyer, P.; Philippe, J. Implications of somatostatin analogues in the treatment of acromegaly. Eur. Endocrinol., 2010, 9(2), 132-135.
[http://dx.doi.org/10.17925/EE.2013.09.02.132] [PMID: 29922369]
[104]
Chin, S.O.; Ku, C.R.; Kim, B.J.; Kim, S.W.; Park, K.H.; Song, K.H.; Oh, S.; Yoon, H.K.; Lee, E.J.; Lee, J.M.; Lim, J.S.; Kim, J.H.; Kim, K.J.; Jin, H.Y.; Kim, D.J.; Lee, K.A.; Moon, S.S.; Lim, D.J.; Shin, D.Y.; Kim, S.H.; Kwon, M.J.; Kim, H.Y.; Kim, J.H.; Kim, D.S.; Kim, C.H. Medical treatment with somatostatin analogues in acromegaly: Position statement. Endocrinol. Metab., 2019, 34(1), 53-62.
[http://dx.doi.org/10.3803/EnM.2019.34.1.53] [PMID: 30912339]
[105]
Shlomo, M.; Melmed, S. Acromegaly. Endocrinol. Metab. Clin. North Am., 2008, 37(1), 101-22.
[PMID: 18226728]
[106]
New drug: Pegvisomant for acromegaly. Aust. Prescr., 2017, 40(5), 199-199.
[http://dx.doi.org/10.18773/austprescr.2017.065] [PMID: 29109606]
[107]
Giustina, A.; Arnaldi, G.; Bogazzi, F.; Cannavò, S.; Colao, A.; De Marinis, L.; De Menis, E.; Degli, U.E.; Giorgino, F.; Grottoli, S.; Lania, A.G.; Maffei, P.; Pivonello, R.; Ghigo, E. Pegvisomant in acromegaly: an update. J. Endocrinol. Invest., 2017, 40(6), 577-589.
[http://dx.doi.org/10.1007/s40618-017-0614-1] [PMID: 28176221]
[108]
Neggers, S.J.C.M.M.; Muhammad, A.; Van Der Lely, A.J. Pegvisomant treatment in acromegaly. Neuroendocrinology, 2016, 103(1), 59-65.
[http://dx.doi.org/10.1159/000381644] [PMID: 25792221]
[109]
Silverstein, J.M. Need for improved monitoring in patients with acromegaly. Endocr. Connect., 2015, 4(4), R59-R67.
[http://dx.doi.org/10.1530/EC-15-0064] [PMID: 26381160]
[110]
Hannon, M.J.; Barkan, A.L.; Drake, W.M. The role of radiotherapy in acromegaly. Neuroendocrinology, 2016, 103(1), 42-49.
[http://dx.doi.org/10.1159/000435776] [PMID: 26088716]
[111]
Eastman, R.C.; Görden, P.; Glatstein, E.; Roth, J. Radiation therapy of acromegaly. Endocrinol. Metab. Clin. North Am., 1992, 21(3), 693-712.
[http://dx.doi.org/10.1016/S0889-8529(18)30209-3] [PMID: 1521519]
[112]
Geraedts, V.J.; Andela, C.D.; Stalla, G.K.; Pereira, A.M.; Van Furth, W.R.; Sievers, C.; Biermasz, N.R. Predictors of quality of life in acromegaly: No consensus on biochemical parameters. Front. Endocrinol., 2017, 8, 40.
[http://dx.doi.org/10.3389/fendo.2017.00040] [PMID: 28316591]
[113]
Ballesteros, H.D.; Briseño, H.P.; Pérez, E,R.; Portocarrero, O.L.A. Differences in quality of life between genders in acromegaly. Endocrinol. Diabetes Metab., 2021, 4(2), e00229.
[http://dx.doi.org/10.1002/edm2.229] [PMID: 33855226]
[114]
Yamamoto, N.; Urai, S.; Fukuoka, H.; Yamamoto, M.; Yoshida, K.; Suzuki, M.; Shichi, H.; Fujita, Y.; Kanie, K.; Iguchi, G.; Takahashi, Y.; Ogawa, W. The effect of aging on quality of life in acromegaly patients under treatment. Front. Endocrinol. (Lausanne), 2022, 13, 819330.
[http://dx.doi.org/10.3389/fendo.2022.819330] [PMID: 35185799]
[115]
Adelman, D.; Liebert, K.J.; Nachtigall, L.B.; Lamerson, M.; Bakker, B. Acromegaly: The disease, its impact on patients, and managing the burden of long-term treatment. Int. J. Gen. Med., 2013, 6, 31-38.
[http://dx.doi.org/10.2147/IJGM.S38594] [PMID: 23359786]
[116]
Lim, D.S.T.; Fleseriu, M. Personalized medical treatment of patients with acromegaly: A review. Endocr. Pract., 2022, 28(3), 321-332.
[http://dx.doi.org/10.1016/j.eprac.2021.12.017] [PMID: 35032649]
[117]
Webb, S.M.; Badia, X. Quality of life in acromegaly. Neuroendocrinology, 2016, 103(1), 106-111.
[http://dx.doi.org/10.1159/000375451] [PMID: 25661974]
[118]
Oliveira, B.A.; Araújo, B.; Dos Santos, T.M.; Ongaratti, B.R.; Leães, R.C.G.S.; Ferreira, N.P.; Pereira, S.L.J.F.; Da, C. Oliveira, M. Health-related quality of life in acromegaly patients: Results from generic and disease-specific questionnaires. Indian J. Endocrinol. Metab., 2020, 24(5), 402-405.
[http://dx.doi.org/10.4103/ijem.IJEM_401_20] [PMID: 33489844]
[119]
Scânteie, C.; Leucuţa, D.C.; Ghervan, C.M.V. Quality of life in patients with acromegaly – A Romanian single center cross-sectional study. Acta Endocrinol. (Bucur.), 2021, 17(1), 42-50.
[http://dx.doi.org/10.4183/aeb.2021.42] [PMID: 34539909]
[120]
Crespo, I.; Valassi, E.; Webb, S.M. Update on quality of life in patients with acromegaly. Pituitary, 2017, 20(1), 185-188.
[http://dx.doi.org/10.1007/s11102-016-0761-y] [PMID: 27730455]
[121]
Giustina, A.; Barkan, A.; Beckers, A.; Biermasz, N.; Biller, B.M.K.; Boguszewski, C.; Bolanowski, M.; Bonert, V.; Bronstein, M.D.; Casanueva, F.F.; Clemmons, D.; Colao, A.; Ferone, D.; Fleseriu, M.; Frara, S.; Gadelha, M.R.; Ghigo, E.; Gurnell, M.; Heaney, A.P.; Ho, K.; Ioachimescu, A.; Katznelson, L.; Kelestimur, F.; Kopchick, J.; Krsek, M.; Lamberts, S.; Losa, M.; Luger, A.; Maffei, P.; Marazuela, M.; Mazziotti, G.; Mercado, M.; Mortini, P.; Neggers, S.; Pereira, A.M.; Petersenn, S.; Puig-Domingo, M.; Salvatori, R.; Shimon, I.; Strasburger, C.; Tsagarakis, S.; van der Lely, A.J.; Wass, J.; Zatelli, M.C.; Melmed, S. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update. J. Clin. Endocrinol. Metab., 2020, 105(4), e937-e946.
[http://dx.doi.org/10.1210/clinem/dgz096] [PMID: 31606735]
[122]
Solomon, E.; Brănișteanu, D.; Dumbravă, A.; Solomon, R.G.; Kiss, L.; Glod, M.; Preda, C. Executive functioning and quality of life in acromegaly. Psychol. Res. Behav. Manag., 2019, 12, 39-44.
[http://dx.doi.org/10.2147/PRBM.S183950] [PMID: 30655710]
[123]
Badia, X.; Webb, S.M.; Prieto, L.; Lara, N. Acromegaly quality of life questionnaire (AcroQoL). Health Qual. Life Outcomes, 2004, 2(1), 13.
[http://dx.doi.org/10.1186/1477-7525-2-13] [PMID: 14987332]
[124]
Danaei, M.; Bahadorizadeh, L.; Dehnad, A.; Mohamadzadeh, S.; Hashemi, M.N.; Khamseh, M.E. Validation of Acromegaly Quality of Life Questionnaire (AcroQoL) for the Iranian population. BMC Psychol., 2022, 10(1), 63.
[http://dx.doi.org/10.1186/s40359-022-00781-0] [PMID: 35287723]
[125]
Guo, X.; Wang, K.; Yu, S.; Gao, L.; Wang, Z.; Zhu, H.; Xing, B.; Zhang, S.; Dong, D. Quality of life and its determinants in patients with treated acromegaly: A cross-sectional nationwide study in China. J. Clin. Endocrinol. Metab., 2021, 106(1), 211-225.
[http://dx.doi.org/10.1210/clinem/dgaa750] [PMID: 33079177]
[126]
Giustina, A.; Bevan, J.S.; Bronstein, M.D.; Casanueva, F.F.; Chanson, P.; Petersenn, S.; Thanh, X.M.T.; Sert, C.; Houchard, A.; Guillemin, I.; Melmed, S. SAGIT®: Clinician-reported outcome instrument for managing acromegaly in clinical practice-development and results from a pilot study. Pituitary, 2016, 19(1), 39-49.
[http://dx.doi.org/10.1007/s11102-015-0681-2] [PMID: 26377024]
[127]
Giustina, A.; Bronstein, M.D.; Chanson, P.; Petersenn, S.; Casanueva, F.F.; Sert, C.; Houchard, A.; Melmed, S. International multicenter validation study of the SAGIT® instrument in acromegaly. J. Clin. Endocrinol. Metab., 2021, 106(12), dgab536.
[http://dx.doi.org/10.1210/clinem/dgab536] [PMID: 34313752]
[128]
Fujio, S.; Arimura, H.; Hirano, H.; Habu, M.; Bohara, M.; Kinoshita, Y.; Arita, K. Changes in quality of life in patients with acromegaly after surgical remission—A prospective study using Sf-36 questionnaire. Endocr. J., 2017, 64(1), 27-38.
[PMID: 27681883]
[129]
Van Der Lely, A.J.; Gomez, R.; Pleil, A.; Badia, X.; Brue, T.; Buchfelder, M.; Burman, P.; Clemmons, D.; Ghigo, E.; Jørgensen, J.O.L.; Luger, A.; Van Der Lans, B.J.; Webb, S.M.; Strasburger, C.J. Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary, 2017, 20(6), 692-701.
[http://dx.doi.org/10.1007/s11102-017-0835-5] [PMID: 28887782]
[130]
Marazuela, M.; Blanco, C.; Bernabeu, I.; Menendez, E.; Villar, R.; Paja, M.; Sampedro, N.M.; Samaniego, M.L.; Díaz, M.M.; Sánchez, C.L. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study. Endocrine, 2022, 75(2), 525-536.
[http://dx.doi.org/10.1007/s12020-021-02900-0] [PMID: 34668173]
[131]
Biermasz, N.R.; Van Thiel, S.W.; Pereira, A.M.; Hoftijzer, H.C.; Van Hemert, A.M.; Smit, J.W.A.; Romijn, J.A.; Roelfsema, F. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J. Clin. Endocrinol. Metab., 2004, 89(11), 5369-5376.
[http://dx.doi.org/10.1210/jc.2004-0669] [PMID: 15531483]
[132]
Gadelha, M.R.; Wildemberg, L.E.; Kasuki, L. The future of somatostatin receptor ligands in acromegaly. J. Clin. Endocrinol. Metab., 2022, 107(2), 297-308.
[http://dx.doi.org/10.1210/clinem/dgab726] [PMID: 34618894]
[133]
Bolanowski, M.; Hubalewska, D.A.; Kos, K.B.; Ruchała, M.; Witek, P.; Zgliczyński, W.; Houchard, A.; Bartmańska, M. Quality of life in patients with acromegaly receiving lanreotide autogel: A real-world observational study. Endokrynol. Pol., 2021, 72(5), 512-519.
[http://dx.doi.org/10.5603/EP.a2021.0075] [PMID: 34647602]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy